Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer

Cancer Immunology, Immunotherapy

Volumn 66, Issue 7, 2017, Pages 927-939

  Lee, Kyu Sang ^a   Kwak, Yoonjin ^a   Ahn, Soyeon ^a   Shin, Eun ^a   Oh, Heung Kwon ^a   Kim, Duck Woo ^a   Kang, Sung Bum ^a   Choe, Gheeyoung ^a,b   Kim, Woo Ho ^b   Lee, Hye Seung ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

CD274; Colorectal cancer; Microsatellite instability; PD L1; Prognosis; Tumor infiltrating immune cells

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; MISMATCH REPAIR PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; BRAF PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; CD3 ANTIGEN; CD8 ANTIGEN; GENETIC MARKER; MICROSATELLITE DNA; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DENSITY; CLINICAL FEATURE; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; GENE MUTATION; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; OVERALL SURVIVAL; PLASMA CELL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; AGED; BIOSYNTHESIS; COLORECTAL NEOPLASMS; GENETIC MARKER; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MUTATION; PATHOLOGY; TISSUE MICROARRAY;

AGED; ANTIGENS, CD274; ANTIGENS, CD3; ANTIGENS, CD8; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; TISSUE ARRAY ANALYSIS;

EID: 85017417465     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-1999-6     Document Type: Article

References (45)

1. Sznol M, Chen L (2013) Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19(5):1021–1034. doi:10.1158/1078-0432.CCR-12-2063
2. Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847–856. doi:10.1158/1535-7163.MCT-14-0983
3. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L (2008) B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635–3643. doi:10.1182/blood-2007-11-123141
4. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7
5. Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M (2016) PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod Pathol 29(9):1104–1112. doi:10.1038/modpathol.2016.95
6. Kim JH, Park HE, Cho NY, Lee HS, Kang GH (2016) Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer 115(4):490–496. doi:10.1038/bjc.2016.211
7. Asaoka Y, Ijichi H, Koike K (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 373(20):1979. doi:10.1056/NEJMc1510353#SA1
8. Wu P, Wu D, Li L, Chai Y, Huang J (2015) PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 10(6):e0131403. doi:10.1371/journal.pone.0131403
9. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L (2013) Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49(9):2233–2242. doi:10.1016/j.ejca.2013.02.015
10. Wang L, Ren F, Wang Q, Baldridge LA, Monn MF, Fisher KW, Sheng W, Zhou X, Du X, Cheng L (2016) Significance of programmed death ligand 1 (PD-L1) immunohistochemical expression in colorectal cancer. Mol Diagn Ther 20(2):175–181. doi:10.1007/s40291-016-0188-1
11. Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, Smith JJ, Garcia-Aguilar J, Sadot E, Ntiamoah P, Markowitz AJ, Shike M, Stadler ZK, Vakiani E, Klimstra DS, Shia J (2016) Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod Pathol 29(11):1433–1442. doi:10.1038/modpathol.2016.139
12. Masugi Y, Nishihara R, Yang J, Mima K, da Silva A, Shi Y, Inamura K, Cao Y, Song M, Nowak JA, Liao X, Nosho K, Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig S, Fuchs CS, Qian ZR, Ogino S (2016) Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut. doi:10.1136/gutjnl-2016-311421
13. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567. doi:10.1038/nature14011
14. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR (2001) Histopathological identification of colon cancer with microsatellite instability. Am J Pathol 158(2):527–535. doi:10.1016/S0002-9440(10)63994-6
15. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvee S, Washetine K, Mouroux J, Venissac N, Poudenx M, Otto J, Sabourin JC, Marquette CH, Hofman V, Hofman P (2016) Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27(1):147–153. doi:10.1093/annonc/mdv489
16. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268
17. Lee HS, Cho SB, Lee HE, Kim MA, Kim JH, Park do J, Kim JH, Yang HK, Lee BL, Kim WH (2007) Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 13(14):4154–4163. doi:10.1158/1078-0432.ccr-07-0173
18. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257
19. Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C, Young JP, Win AK, Hopper JL, Crook A, von Deimling A, Jenkins MA, Buchanan DD, Gill AJ (2013) BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol 37(10):1592–1602. doi:10.1097/PAS.0b013e31828f233d
20. Nam SK, Yun S, Koh J, Kwak Y, Seo AN, Park KU, Kim DW, Kang SB, Kim WH, Lee HS (2016) BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS One 11(3):e0151865. doi:10.1371/journal.pone.0151865
21. Greenhalgh T (1997) How to read a paper. Statistics for the non-statistician. I: Different types of data need different statistical tests. BMJ 315(7104):364–366
22. Christine D, John R (2004) Statistics without maths for psychology: using SPSS for windows. Prentice Hall, London
23. Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M, Kloor M (2013) BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer 133(7):1624–1630. doi:10.1002/ijc.28183
24. Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M (2017) Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Mod Pathol 30(2):278–285. doi:10.1038/modpathol.2016.185
25. Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J, Lappe M, Kuss AW, Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K, Lehrach H, Schweiger MR (2010) Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 5(12):e15661. doi:10.1371/journal.pone.0015661
26. Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS, Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G, Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. doi:10.1016/j.celrep.2016.03.075
27. Lal N, Beggs AD, Willcox BE, Middleton GW (2015) An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology 4(3):e976052. doi:10.4161/2162402X.2014.976052
28. Boissiere-Michot F, Lazennec G, Frugier H, Jarlier M, Roca L, Duffour J, Du Paty E, Laune D, Blanchard F, Le Pessot F, Sabourin JC, Bibeau F (2014) Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology 3:e29256. doi:10.4161/onci.29256
29. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5(1):43–51. doi:10.1158/2159-8290.CD-14-0863
30. Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1):1–14. doi:10.1111/j.1365-2567.2007.02587.x
31. Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ (2016) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. doi:10.1136/gutjnl-2015-310839
32. Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, van der Velden J, Kenter GG, de Gruijl TD, Jordanova ES (2016) Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 29(7):753–763. doi:10.1038/modpathol.2016.64
33. Bellmunt J, Mullane SA, Werner L, Fay AP, Callea M, Leow JJ, Taplin ME, Choueiri TK, Hodi FS, Freeman GJ, Signoretti S (2015) Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 26(4):812–817. doi:10.1093/annonc/mdv009
34. Zou MX, Peng AB, Lv GH, Wang XB, Li J, She XL, Jiang Y (2016) Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. Am J Transl Res 8(7):3274–3287
35. Shigehiro Koganemaru NI, Miura Y, Fukui Y, Ozaki Y, Tomizawa K, Hanaoka Y, Toda S, Suyama K, Tanabe Y, Moriyama J, Fujii T, Matoba S, Kuroyanagi H, Takano T (2016) Prognostic value of programmed death-ligand 1 (PD-L1) expression in patients with stage III colorectal cancer. J Clin Oncol 34(suppl; abstr 3568) [Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016]
36. He J, Hu Y, Hu M, Li B (2015) Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 5:13110. doi:10.1038/srep13110
37. Di Caro G, Marchesi F, Laghi L, Grizzi F (2013) Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med 17(9):1088–1095. doi:10.1111/jcmm.12117
38. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA (2015) PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell Melanoma Res 28(3):245–253. doi:10.1111/pcmr.12340
39. Callea M, Albiges L, Gupta M, Cheng SC, Genega EM, Fay AP, Song J, Carvo I, Bhatt RS, Atkins MB, Hodi FS, Choueiri TK, McDermott DF, Freeman GJ, Signoretti S (2015) Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol Res 3(10):1158–1164. doi:10.1158/2326-6066.CIR-15-0043
40. Barsoum IB, Smallwood CA, Siemens DR, Graham CH (2014) A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res 74(3):665–674. doi:10.1158/0008-5472.CAN-13-0992
41. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S (2014) PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211(5):781–790. doi:10.1084/jem.20131916
42. Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013) Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14(8):16365–16385. doi:10.3390/ijms140816365
43. Kocarnik JM, Shiovitz S, Phipps AI (2015) Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol Rep (Oxf) 3(4):269–276. doi:10.1093/gastro/gov046
44. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230):124–128. doi:10.1126/science.aaa1348
45. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I (2014) Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25(10):1935–1940. doi:10.1093/annonc/mdu242